Jochen Hammes1, Philipp Täger2, Alexander Drzezga2. 1. Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany jochen.hammes@uk-koeln.de. 2. Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Abstract
Prostate-specific membrane antigen (PSMA) PET/CT has a high diagnostic accuracy for lesion detection in metastatic prostate cancer, including bone metastases. Novel therapeutic approaches require valid biomarkers for standardized disease staging and for evaluation of progression and therapy response. Here, we introduce EBONI (Evaluation of Bone Involvement), a software tool to automatically quantify the bone metastasis load in PSMA PET/CT. Lesion quantity, mean and maximum lesional SUV, z score, and percentage of affected bone volume are determined. EBONI is open source and freely available. Methods: To validate EBONI, the results of automated quantification of 38 PSMA PET/CT scans with different levels of bone involvement were compared with visual expert reading. The influence of SUV threshold and Hounsfield unit thresholds was analyzed. Results: A high correlation between bone lesion quantity as determined visually and automatically was found (SUVmax, r2 = 0.97; SUVmean, r2 = 0.88; lesion count, r2 = 0.97). The Hounsfield unit threshold had no significant influence, whereas an SUV threshold of 2.5 proved optimal for automated lesion quantification. The systematic error of false-positive tissue misclassification was low, occurred mainly around the salivary and lacrimal glands, and could easily be corrected. There were no false-negative ratings. Conclusion: EBONI analysis is robust, quick (<3 min per scan), and 100% reproducible. It allows rater-independent quantification of bone metastasis in metastatic prostate cancer. It provides lesion quantification equivalent to that of visual assessment, as well as providing complementary information. It can be easily implemented as an add-on to visual analysis of PSMA PET/CT scans and has the potential to reduce turnaround time.
Prostate-specific membrane antigen (PSMA) PET/CT has a high diagnostic accuracy for lesion detection in metastatic prostate cancer, including bone metastases. Novel therapeutic approaches require valid biomarkers for standardized disease staging and for evaluation of progression and therapy response. Here, we introduce EBONI (Evaluation of Bone Involvement), a software tool to automatically quantify the bone metastasis load in PSMA PET/CT. Lesion quantity, mean and maximum lesional SUV, z score, and percentage of affected bone volume are determined. EBONI is open source and freely available. Methods: To validate EBONI, the results of automated quantification of 38 PSMA PET/CT scans with different levels of bone involvement were compared with visual expert reading. The influence of SUV threshold and Hounsfield unit thresholds was analyzed. Results: A high correlation between bone lesion quantity as determined visually and automatically was found (SUVmax, r2 = 0.97; SUVmean, r2 = 0.88; lesion count, r2 = 0.97). The Hounsfield unit threshold had no significant influence, whereas an SUV threshold of 2.5 proved optimal for automated lesion quantification. The systematic error of false-positive tissue misclassification was low, occurred mainly around the salivary and lacrimal glands, and could easily be corrected. There were no false-negative ratings. Conclusion: EBONI analysis is robust, quick (<3 min per scan), and 100% reproducible. It allows rater-independent quantification of bone metastasis in metastatic prostate cancer. It provides lesion quantification equivalent to that of visual assessment, as well as providing complementary information. It can be easily implemented as an add-on to visual analysis of PSMA PET/CT scans and has the potential to reduce turnaround time.
Authors: Andrei Gafita; Marie Bieth; Markus Krönke; Giles Tetteh; Fernando Navarro; Hui Wang; Elisabeth Günther; Bjoern Menze; Wolfgang A Weber; Matthias Eiber Journal: J Nucl Med Date: 2019-03-08 Impact factor: 10.057
Authors: Jochen Hammes; Melanie Hohberg; Philipp Täger; Markus Wild; Boris Zlatopolskiy; Philipp Krapf; Bernd Neumaier; Klaus Schomäcker; Carsten Kobe; Matthias Schmidt; Markus Dietlein; Alexander Drzezga Journal: PLoS One Date: 2018-12-20 Impact factor: 3.240
Authors: Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri Journal: Clinics (Sao Paulo) Date: 2018-09-21 Impact factor: 2.365
Authors: Philipp E Hartrampf; Marieke Heinrich; Anna Katharina Seitz; Joachim Brumberg; Ioannis Sokolakis; Charis Kalogirou; Andreas Schirbel; Hubert Kübler; Andreas K Buck; Constantin Lapa; Markus Krebs Journal: J Clin Med Date: 2020-05-08 Impact factor: 4.241